PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1270354
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1270354
Vascular Endothelial Growth Factor (VEGF) Inhibitors Market size was valued at USD 8,900.7 million in 2022, expanding at a CAGR of 9.1% from 2023 to 2030.
Initiating a network of signaling mechanisms that support endothelial cell growth, motility, and survival after the activation of the VEGF-receptor pathway is one of the main functions of VEGF, one of the main regulators of angiogenesis. At the moment, chemotherapy is frequently used in conjunction with angiogenesis inhibitors.
Vascular Endothelial Growth Factor (VEGF) Inhibitors Market- Market Dynamics
The vascular endothelial growth factor (VEGF) inhibitor market is anticipated to be driven by the rising frequency of cancer and macular degeneration illnesses. For instance, age-related macular degeneration will affect 8-7% of the world's population in August 2022, according to this systematic review and meta-analysis published by the National Library of Medicine, a US-based medical library, with the disease affecting 196 million people in 2020 and increasing to 288 million by 2040.Anti-vascular endothelial growth factor (anti-VEGF) medications slow the disease's progression and enhance vision. An inhibitor of the vascular endothelial growth factor (VEGF) inhibits and limits tumor growth in malignancies. As a result, during the course of the projection period, the market for VEGF inhibitors will rise due to the rising incidence of macular degeneration and cancer.
Additionally, for the treatment of individuals with significant tumor growth, more and more medications are getting approved. For instance, the new Eylea (aflibercept) injection pre-filled syringe that Bayer AG got clearance for from the European Medicines Agency (EMA) in April 2020 would give ophthalmologists a more effective and convenient way to deliver EYLEA across all approved indications. Compared to the current vial's intravitreal injection method, the pre-filled syringe is easier to prepare.
The Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market is segmented based on Drugs Type, Route of Administration, Application, and Region.
Based on the application, the oncology segment is growing at the highest CAGR over the forecast period. The growth in the segment is attributed to the increasing prevalence of cancer across the globe. These inhibitors are used in the treatment of cancer such as. As per the World Cancer research Fund International, in 2020, there will be 18.1 million new cases of cancer worldwide. 9.3 million Of these instances involved men, while 8.8 million involved women.
Vascular Endothelial Growth Factor (VEGF) Inhibitors Market- Geographical Insights
North America is expected to dominate the market during the forecast period. The regional growth is owing to the presence of robust healthcare infrastructure. Moreover, the increasing prevalence of the cancer is another important factor that penetrate the market expansion. For instance, according to the American Cancer Society, in the United States, there are anticipated to be 1,918,030 new cancer cases and 609,360 cancer deaths in 2022, with lung cancer as the primary cause of death accounting for about 350 of those fatalities daily. On the other hand, the Asia Pacific region garner a significant market share in 2022 owing to the increasing incidence of cancer especially in the country like India, China and Others. In addition, the increasing cases related to the eye disease is also fuel the market expansion.
In February 2022, Angiogenesis, Exudation and Degeneration is where Genentech, a part of the Roche Group, will present new two-year data from its Phase III studies of the drugs VabysmoTM (faricimab-svoa) and SusvimoTM (ranibizumab injection) 100 mg/mL for intravitreal administration via ocular implant.
This proposed research study on the Vascular Endothelial Growth Factor (VEGF) Inhibitors market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Vascular Endothelial Growth Factor (VEGF) Inhibitors market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Vascular Endothelial Growth Factor (VEGF) Inhibitors market
Impact of COVID-19 on Vascular Endothelial Growth Factor (VEGF) Inhibitors market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Vascular Endothelial Growth Factor (VEGF) Inhibitors market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the Vascular Endothelial Growth Factor (VEGF) Inhibitors market, we have also included competitive landscape and key innovator analysis for the Vascular Endothelial Growth Factor (VEGF) Inhibitors market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Vascular Endothelial Growth Factor (VEGF) Inhibitors market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
The global Vascular Endothelial Growth Factor (VEGF) Inhibitors market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET KEY PLAYERS
Abbott (U.S.)
Sanofi (France)
AstraZeneca (U.K.)
Bristol-Myers Squibb Company (U.S.)
F. Hoffmann-La Roche Ltd (Switzerland)
Bayer AG (Germany)
Pfizer Inc (U.S.)
Teva Pharmaceutical Industries Ltd (Israel)
Novartis AG (Switzerland)
Genentech, Inc (U.S.)
Regeneron Pharmaceuticals Inc (U.S.)
Eisai Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Exelixis, Inc. (U.S.).
GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET, BY DRUGS TYPE
Avastin
Tecentriq
Cometriq
Eylea
Others
GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
Oral
Injectable
Others
GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET, BY APPLICATION
Oncology
Ophthalmology
Others
GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA